How to design preclinical studies in nanomedicine and cell therapy to maximize the prospects of clinical translation

John P.A. Ioannidis, Betty Y.S. Kim, Alan Trounson

Research output: Contribution to journalArticlepeer-review

52 Scopus citations


The clinical translation of promising products, technologies and interventions from the disciplines of nanomedicine and cell therapy has been slow and inefficient. In part, translation has been hampered by suboptimal research practices that propagate biases and hinder reproducibility. These include the publication of small and underpowered preclinical studies, suboptimal study design (in particular, biased allocation of experimental groups, experimenter bias and lack of necessary controls), the use of uncharacterized or poorly characterized materials, poor understanding of the relevant biology and mechanisms, poor use of statistics, large between-model heterogeneity, absence of replication, lack of interdisciplinarity, poor scientific training in study design and methods, a culture that does not incentivize transparency and sharing, poor or selective reporting, misaligned incentives and rewards, high costs of materials and protocols, and complexity of the developed products, technologies and interventions. In this Perspective, we discuss special manifestations of these problems in nanomedicine and in cell therapy, and describe mitigating strategies. Progress on reducing bias and enhancing reproducibility early on ought to enhance the translational potential of biomedical findings and technologies.

Original languageEnglish (US)
Pages (from-to)797-809
Number of pages13
JournalNature Biomedical Engineering
Issue number11
StatePublished - Nov 1 2018

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Medicine (miscellaneous)
  • Biomedical Engineering
  • Computer Science Applications


Dive into the research topics of 'How to design preclinical studies in nanomedicine and cell therapy to maximize the prospects of clinical translation'. Together they form a unique fingerprint.

Cite this